Up to the present, the identification of neurochemical alterations underlying Alzheimer's disease allowed for the development of the first generation of therapies that are somewhat specific for this disorder. Although both cholinesterase inhibitors and NMDA receptor blockade have well-proven efficacy levels, the clinical outcomes of patients receiving such treatments are rather limited; with many authors considering them as “symptomatic” treatments. In this context, it is safe to say that although the microscopic alterations present in AD have been well known for over a century, we have failed to identify therapeutic agents able to block the synthesis and aggregation of amyloid β42 or the formation of neurofibrillary tangles. Some new therapeutic strategies have however been explored in the last few years. This paper aimed at reviewing the evidence supporting these new “disease modifying” therapeutic options, including anti-amyloid and anti-Tau strategies

With the advancement of Alzheimer’s disease as well as other types of dementia, in addition to the cognitive decline, psychiatric symptoms have been outlined, including psychotic symptoms. The aim of the study is to review the available results on the antipsychotic treatment of Alzheimer’s disease associated psychotic symptoms. The main objective of the study is to evaluate the efficacy of the treatment. The second objective is to assess the tolerability of this treatment. Double-blind, randomized, placebo-controlled trials, which took place over the course of at least 4 weeks, have been searched. Studies that compared one atypical antipsychotic to placebo, as well as more atypical antipsychotics, compared one to another, have been taken into account. In total 17 studies have been selected. The efficacy of the atypical antipsychotics has proven to be significant in most studies. Moreover, antipsychotic medication, such as risperidone, aripiprazole, olanzapine, quetiapine and pimavanserin, has been well tolerated. Atypical antipsychotics are the treatment of choice for psychotic symptoms in dementia. Despite the consistent results present in the literature up to this point, various antipsychotics remain insufficiently studied and would need more generous sample sizes for their outcomes to be substantiated.

Background: Suicide ideation and behaviors are directly linked to the risk of death by suicide. In Romania, as well as worldwide, increased suicide rates were observed in the recent past, more so in the context of the COVID-19 pandemic. The purpose of this study was to investigate the influence of psychosocial factors, quality of life (QOL), and loneliness dimensions and adverse life antecedents on suicide ideation (SI) and prolonged sadness (PS). Methods: This cross-sectional quantitative research study used a CATI data gathering method to investigate 1102 randomly selected individuals over 18 years of age regarding various determinants of SI and PS. Data were collected in June 2021. Descriptive, inferential, and multivariate statistics were used for data analysis. Results: SI was negatively correlated with all the assessed psychosocial factors, more significantly with family relationships, wealth, health, social relationships, and affective life. Stronger correlations were observed when investigating the state of prolonged sadness, sex, and affective lives along with health and income, which were more influential. SI was negatively correlated with QOL and positively correlated with adverse life events and total loneliness scores. Lesser educated youngsters with reduced overall happiness and a history of depression, self-harm, and trauma were at greater risk of developing SI. Conclusions: This is the first national study exploring the suicide ideation and prolonged sadness in relation to psychosocial factors, quality of life, and adverse life events. These results have important implications for suicide prevention programs, which should be designed in accordance with similar studies.

Background and aim: Emotional cognitive coping strategies are closely correlated with depression and suicide risk. The aim of this study is to explore the particular features of cognitive-emotional coping and their impact on depression levels and suicidal ideation. Methods: The study included a total number of 131 participants, 65 with a clinical diagnosis of depression and 66 controls. Instruments used were: Cognitive Emotion Regulation Questionnaire (CERQ), Columbia Suicide Severity Rating Scale (C-SSRS), Depression Anxiety Stress Scale (DASS21R), Montgomery-Asberg Depression Scale (MADRS), in order to assess the differences between depressive and non-depressive individuals in relation to coping strategies. Results and conclusion: The findings, based on the statistical analysis of the scores obtained on the various psychometric scales, showed significant differences between depressive and non-depressive patients. Also, cognitive-emotional strategies could represent a good predictor to be used in the prevention of suicide risk in depressed patients.